AlphAIAlphAI — Financial news for AI agents
Stock TitanMAY 53 min read$CLNN

SymBiosis II LLC, major Clene (NASDAQ: CLNN) holder, sells 78,679 shares

SymBiosis II LLC, an entity associated with major Clene (NASDAQ: CLNN) shareholder Ugwumba Chidozie, reported selling a total of 78,679 shares of Clene Inc. common stock in two open-market transactions. These sales occurred on May 1, 2026, for 5,795 shares at $6.01, and on May 4, 2026, for 72,884 shares at $6.80. Following these transactions, SymBiosis II LLC indirectly holds 198,890 shares of Clene Inc.

Original reporting
Stock Titan
Published May 5, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 5, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SymBiosis II LLC, major Clene (NASDAQ: CLNN) holder, sells 78,679 shares — source image
Source · Stock Titan
Decision brief

The 30-second read

$CLNNNeutralMed
01

Why it matters

The insider sales could lead to short-term price adjustments; however, the overall impact depends on broader market conditions and investor sentiment.

02

Market read

While insider transactions are noteworthy, they should be interpreted in context; current relevance is moderate.

03

What to watch

Market conditions, upcoming catalysts, and overall company performance should be considered before making trading decisions.

Relevance 6/10Timing: Immediate, as the sale occurred on May 1 and May 4, 2026.

Background

SymBiosis II LLC, associated with major shareholder Ugwumba Chidozie, sold a total of 78,679 shares of Clene Inc. in two transactions, indicating a possible shift in insider sentiment.

Company-level read

Ticker impact

$CLNNNeutralMedium confidence
Context

The insider sale by SymBiosis II LLC, a major shareholder, indicates potential insider sentiment shift.

Expected impact

Potential short-term downward pressure; long-term impact uncertain.

Evidence & confidence

Insider sales can be a sign of profit realization but do not necessarily indicate negative fundamentals; market reaction depends on broader context.

Market effects

Sector

The sale may reflect broader sentiment in the life sciences sector, but limited impact on overall sector trend.

Regional

Minimal regional impact; specific to company insiders.

Global

Negligible

Counterpoint

What could challenge this read

Insider selling does not necessarily indicate negative outlook; it could be for personal liquidity or diversification.

Key entities

  • Entity
    SymBiosis II LLC

    Major shareholder of Clene Inc.

  • Individual
    Ugwumba Chidozie

    Associated with SymBiosis II LLC and major shareholder of Clene Inc.

Read at source← All news

Related articles

OCT 2
$CLNNMed

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Clene Inc (CLNN) plans to submit an FDA application for its ALS drug CNM-Au8 in Q4, aiming for a mid-2027 decision. CEO Etherington cited survival benefits and neurofilament light changes as supporting data. The company has held five FDA meetings and completed financing to support the filing. If approved, CNM-Au8 could address thousands of patients annually, with Clene working on insurer and payer agreements.

finance.yahoo.com2 min
AUG 19
$CLNNMedAI 8/10

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.

yahoo.com2 min
AUG 14
$CLNNMed

CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional

SEC EDGAR 8-K6 min
OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 8
$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

marketscreener.com1 min
OCT 8
$PINSMed

Pinterest (PINS), Why Is It Back In The Spotlight?

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

simplywall.st2 min